Switch to:
Also traded in: Austria, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.64
NAS:WBA's Cash-to-Debt is ranked higher than
55% of the 364 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.53 vs. NAS:WBA: 0.64 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:WBA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.38 Max: No Debt
Current: 0.64
Equity-to-Asset 0.41
NAS:WBA's Equity-to-Asset is ranked lower than
53% of the 359 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.42 vs. NAS:WBA: 0.41 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:WBA' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41  Med: 0.55 Max: 0.64
Current: 0.41
0.41
0.64
Interest Coverage 8.32
NAS:WBA's Interest Coverage is ranked lower than
69% of the 328 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 19.81 vs. NAS:WBA: 8.32 )
Ranked among companies with meaningful Interest Coverage only.
NAS:WBA' s Interest Coverage Range Over the Past 10 Years
Min: 7.72  Med: 39.24 Max: No Debt
Current: 8.32
Piotroski F-Score: 7
Altman Z-Score: 3.68
Beneish M-Score: -2.81
WACC vs ROIC
6.37%
11.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 4.78
NAS:WBA's Operating Margin % is ranked higher than
69% of the 364 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.88 vs. NAS:WBA: 4.78 )
Ranked among companies with meaningful Operating Margin % only.
NAS:WBA' s Operating Margin % Range Over the Past 10 Years
Min: 4.51  Med: 5.31 Max: 6.05
Current: 4.78
4.51
6.05
Net Margin % 3.69
NAS:WBA's Net Margin % is ranked higher than
74% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.94 vs. NAS:WBA: 3.69 )
Ranked among companies with meaningful Net Margin % only.
NAS:WBA' s Net Margin % Range Over the Past 10 Years
Min: 2.53  Med: 3.55 Max: 4.08
Current: 3.69
2.53
4.08
ROE % 14.28
NAS:WBA's ROE % is ranked higher than
73% of the 357 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.73 vs. NAS:WBA: 14.28 )
Ranked among companies with meaningful ROE % only.
NAS:WBA' s ROE % Range Over the Past 10 Years
Min: 9.67  Med: 14.63 Max: 19.24
Current: 14.28
9.67
19.24
ROA % 6.00
NAS:WBA's ROA % is ranked higher than
71% of the 368 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.40 vs. NAS:WBA: 6.00 )
Ranked among companies with meaningful ROA % only.
NAS:WBA' s ROA % Range Over the Past 10 Years
Min: 5.31  Med: 8.05 Max: 11.2
Current: 6
5.31
11.2
ROC (Joel Greenblatt) % 39.31
NAS:WBA's ROC (Joel Greenblatt) % is ranked higher than
84% of the 365 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.30 vs. NAS:WBA: 39.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:WBA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 24.31  Med: 29.67 Max: 39.26
Current: 39.31
24.31
39.26
3-Year Revenue Growth Rate 12.50
NAS:WBA's 3-Year Revenue Growth Rate is ranked higher than
80% of the 331 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.10 vs. NAS:WBA: 12.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:WBA' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0.5  Med: 12.5 Max: 16.5
Current: 12.5
0.5
16.5
3-Year EBITDA Growth Rate 7.90
NAS:WBA's 3-Year EBITDA Growth Rate is ranked higher than
54% of the 299 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.70 vs. NAS:WBA: 7.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:WBA' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -1.1  Med: 12.3 Max: 18.3
Current: 7.9
-1.1
18.3
3-Year EPS without NRI Growth Rate 12.70
NAS:WBA's 3-Year EPS without NRI Growth Rate is ranked higher than
60% of the 265 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.60 vs. NAS:WBA: 12.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:WBA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -12.1  Med: 14.1 Max: 20
Current: 12.7
-12.1
20
GuruFocus has detected 6 Warning Signs with Walgreens Boots Alliance Inc $NAS:WBA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:WBA's 30-Y Financials

Financials (Next Earnings Date: 2017-09-29 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

WBA Guru Trades in Q3 2016

Joel Greenblatt 831,783 sh (+76.83%)
Pioneer Investments 229,753 sh (+31.03%)
Ken Fisher 6,726 sh (+4.30%)
First Pacific Advisors 86,550 sh (+2.61%)
Mario Gabelli 451,894 sh (+0.40%)
Vanguard Health Care Fund 8,048,160 sh (unchged)
George Soros 25,558 sh (unchged)
Keeley Asset Management Corp 3,125 sh (unchged)
Dodge & Cox 8,579 sh (unchged)
Tom Gayner 2,135,000 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
John Griffin 1,681,000 sh (unchged)
Mairs and Power 11,445 sh (unchged)
Jim Simons Sold Out
Jana Partners Sold Out
Leon Cooperman 1,086,300 sh (-11.17%)
Andreas Halvorsen 1,191,911 sh (-65.65%)
Paul Tudor Jones 6,506 sh (-79.20%)
» More
Q4 2016

WBA Guru Trades in Q4 2016

Larry Robbins 1,500,000 sh (New)
Jim Simons 1,928,300 sh (New)
Andreas Halvorsen 7,899,951 sh (+562.80%)
Paul Tudor Jones 34,315 sh (+427.44%)
Ken Fisher 7,811 sh (+16.13%)
Mairs and Power 13,045 sh (+13.98%)
Vanguard Health Care Fund 8,048,160 sh (unchged)
Keeley Asset Management Corp 3,125 sh (unchged)
Tom Gayner 2,135,000 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
George Soros Sold Out
John Griffin Sold Out
First Pacific Advisors Sold Out
Mario Gabelli 450,379 sh (-0.34%)
Dodge & Cox 8,079 sh (-5.83%)
Leon Cooperman 934,100 sh (-14.01%)
Joel Greenblatt 687,941 sh (-17.29%)
Pioneer Investments 182,995 sh (-20.35%)
» More
Q1 2017

WBA Guru Trades in Q1 2017

Lee Ainslie 1,013,553 sh (New)
Steven Cohen 327,100 sh (New)
Ray Dalio 20,187 sh (New)
Andreas Halvorsen 12,063,404 sh (+52.70%)
Paul Tudor Jones 38,334 sh (+11.71%)
Mairs and Power 14,364 sh (+10.11%)
Pioneer Investments 186,947 sh (+2.16%)
Vanguard Health Care Fund 8,048,160 sh (unchged)
Tom Gayner 2,135,000 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
Larry Robbins Sold Out
Mario Gabelli 444,614 sh (-1.28%)
Dodge & Cox 7,569 sh (-6.31%)
Ken Fisher 7,155 sh (-8.40%)
Leon Cooperman 826,103 sh (-11.56%)
Joel Greenblatt 330,643 sh (-51.94%)
Jim Simons 23,100 sh (-98.80%)
» More
Q2 2017

WBA Guru Trades in Q2 2017

John Hussman 50,000 sh (New)
Larry Robbins 1,747,858 sh (New)
John Buckingham 12,237 sh (New)
Ray Dalio 62,547 sh (+209.84%)
Jim Simons 51,300 sh (+122.08%)
Paul Tudor Jones 68,703 sh (+79.22%)
Joel Greenblatt 566,818 sh (+71.43%)
Mairs and Power 15,916 sh (+10.80%)
Mario Gabelli 464,409 sh (+4.45%)
Tom Gayner 2,135,000 sh (unchged)
Vanguard Health Care Fund 8,048,160 sh (unchged)
Dodge & Cox 7,569 sh (unchged)
Bill Gates 3,475,398 sh (unchged)
Leon Cooperman Sold Out
Steven Cohen Sold Out
Ken Fisher 7,134 sh (-0.29%)
Pioneer Investments 169,248 sh (-9.47%)
Andreas Halvorsen 3,012,489 sh (-75.03%)
Lee Ainslie 251,710 sh (-75.17%)
» More
» Details

Insider Trades

Latest Guru Trades with WBA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-06-30 Add 71.43%0.26%$76.34 - $86.54 $ 80.03-3%566,818
Mario Gabelli 2017-06-30 Add 4.45%0.01%$76.34 - $86.54 $ 80.03-3%464,409
Ken Fisher 2017-06-30 Reduce -0.29%$76.34 - $86.54 $ 80.03-3%7,134
Leon Cooperman 2017-06-30 Sold Out 2.76%$76.34 - $86.54 $ 80.03-3%0
Leon Cooperman 2017-03-31 Reduce -11.56%0.39%$80.47 - $87.61 $ 80.03-5%826,103
Mario Gabelli 2017-03-31 Reduce -1.28%$80.47 - $87.61 $ 80.03-5%444,614
Joel Greenblatt 2017-03-31 Reduce -51.94%0.38%$80.47 - $87.61 $ 80.03-5%330,643
Dodge & Cox 2017-03-31 Reduce -6.31%$80.47 - $87.61 $ 80.03-5%7,569
Ken Fisher 2017-03-31 Reduce -8.40%$80.47 - $87.61 $ 80.03-5%7,155
Leon Cooperman 2016-12-31 Reduce -14.01%0.38%$77.18 - $87.73 $ 80.03-3%934,100
Joel Greenblatt 2016-12-31 Reduce -17.29%0.15%$77.18 - $87.73 $ 80.03-3%687,941
Mario Gabelli 2016-12-31 Reduce -0.34%$77.18 - $87.73 $ 80.03-3%450,379
Dodge & Cox 2016-12-31 Reduce -5.83%$77.18 - $87.73 $ 80.03-3%8,079
Ken Fisher 2016-12-31 Add 16.13%$77.18 - $87.73 $ 80.03-3%7,811
George Soros 2016-12-31 Sold Out 0.08%$77.18 - $87.73 $ 80.03-3%0
Leon Cooperman 2016-09-30 Reduce -11.17%0.32%$78.95 - $84.67 $ 80.03-2%1,086,300
Joel Greenblatt 2016-09-30 Add 76.83%0.38%$78.95 - $84.67 $ 80.03-2%831,783
Mario Gabelli 2016-09-30 Add 0.40%$78.95 - $84.67 $ 80.03-2%451,894
Ken Fisher 2016-09-30 Add 4.30%$78.95 - $84.67 $ 80.03-2%6,726
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers    NAICS: 446110    SIC: 5912
Compare:NYSE:RAD, NAS:PETS, NYSE:GNC, OTCPK:OMHE, OTCPK:HEWA » details
Traded in other countries:WBA.Austria, W8A.Germany, WBA.Mexico, WBA.Switzerland, 0R0C.UK,
Headquarter Location:USA
Walgreens Boots Alliance Inc operates pharmacy store chain in the United States. It provides consumer goods and services, pharmacy, and health and wellness services through drug stores, as well as mail, and by telephone and online.

Walgreens is one of the nation's largest retail pharmacies, with about 8,175 drugstores throughout the United States. This large network of stores allows the firm the ability to reach a significant portion of the U.S. population, providing excellent brand recognition. Prescription drugs account for about two thirds of sales, with the balance attributable to front-store products such as grocery, health, and beauty items. The firm also operates in-store health clinics.

Top Ranked Articles about Walgreens Boots Alliance Inc

John Buckingham Picks Up 4 Retailers in 2nd Quarter Guru invests in Walgreens, Kroger, Amazon and Home Depot
AFAM Capital’s John Buckingham (Trades, Portfolio) established 18 new holdings during the second quarter, four of which were in retailers. Read more...
What Doesn’t Kill You Makes You Stronger We believe the lack of enthusiasm for stocks and today’s set of circumstances provide a blueprint to future profits in US large-cap stocks
A few years ago, there was a TV commercial for the Toyota Camry featuring singer Kelly Clarkson and ESPN’s legendary sportscaster Chris Berman. It pointed out all the positive attributes of the new car with Clarkson’s hit, “Stronger,” playing in the background. As we look out into the second half of 2017, it is important to understand we believe the U.S. stock market has tried to “kill” investor enthusiasm. We would argue this enhances the position of the value-oriented and long duration equity manager in a way that does not kill us but makes us "stronger." Read more...
Introducing the Stock Screen That Tells You Companies With Recently Released Earnings GuruFocus developers release the 'Most Recent Financial Update' feature just in time for earnings season
Developers at GuruFocus today added a new feature to the All-in-One Screener that makes keeping tabs on companies’ earnings releases easier. Read more...
Options Trades: covered-call reports for Cisco Systems, Facebook, Procter & Gamble, Walgreens Boots Alliance and Walmart Stores Inc.
InvestorsObserver releases covered-call reports for ACADIA Pharmaceuticals, Aerie Pharmaceuticals, Best Buy Inc., Marathon Oil Corporation and Walgreens Boots Alliance
Walgreens Boots Alliance, Inc. (Nasdaq: WBA) and Comic Relief to Ring The Nasdaq Stock Market Closing Bell in Celebration of Red Nose Day
General Mills, Hi-Crush Partners LP, JP Morgan Chase, PayPal Holdings Inc., and Walgreens Boots Alliance and more offer option-trading opportunities that offer returns of more than 21%
Covered Call reports for Apple, Bank of America, Cardinal Health, CVS Health Corp., and Walgreens Boots Alliance include trade ideas that offer returns of 23% or more!
Francis Chou Adds to Valeant, Trims Sears in 4th Quarter Successful guru reports quarterly portfolio
Francis Chou (Trades, Portfolio), founder of Chou Associates Management, started an investment club in 1981 with six of his fellow telephone repairman. Throughout the next five years, Chou worked as a retail analyst at GW Asset Management where he met “Canadian Warren Buffett (Trades, Portfolio)” Prem Watsa (Trades, Portfolio). The successful guru established his flagship fund, the Chou Associate Fund, in 1986. On an annual basis, Chou’s fund outperformed the Standard & Poor’s 500 index benchmark by approximately 7% on Read more...
Insider Buys Highlight for Week of Feb. 6 Insiders bought shares of Walgreens Boots Alliance and Qualcomm
Walgreens Boots Alliance Inc. (NASDAQ:WBA): Co-COO Ornella Barra bought 124,000 shares Read more...

Ratios

vs
industry
vs
history
PE Ratio 20.21
WBA's PE Ratio is ranked higher than
52% of the 304 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.17 vs. WBA: 20.21 )
Ranked among companies with meaningful PE Ratio only.
WBA' s PE Ratio Range Over the Past 10 Years
Min: 10.2  Med: 19.25 Max: 35.8
Current: 20.21
10.2
35.8
Forward PE Ratio 14.79
WBA's Forward PE Ratio is ranked higher than
72% of the 65 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 17.76 vs. WBA: 14.79 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 20.21
WBA's PE Ratio without NRI is ranked higher than
53% of the 302 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.55 vs. WBA: 20.21 )
Ranked among companies with meaningful PE Ratio without NRI only.
WBA' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.2  Med: 19.25 Max: 35.8
Current: 20.21
10.2
35.8
Price-to-Owner-Earnings 12.75
WBA's Price-to-Owner-Earnings is ranked higher than
73% of the 203 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 21.21 vs. WBA: 12.75 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
WBA' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.76  Med: 15.79 Max: 40.18
Current: 12.75
8.76
40.18
PB Ratio 2.80
WBA's PB Ratio is ranked lower than
66% of the 352 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.77 vs. WBA: 2.80 )
Ranked among companies with meaningful PB Ratio only.
WBA' s PB Ratio Range Over the Past 10 Years
Min: 1.6  Med: 2.76 Max: 5.07
Current: 2.8
1.6
5.07
PS Ratio 0.74
WBA's PS Ratio is ranked lower than
65% of the 356 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.49 vs. WBA: 0.74 )
Ranked among companies with meaningful PS Ratio only.
WBA' s PS Ratio Range Over the Past 10 Years
Min: 0.36  Med: 0.65 Max: 1.09
Current: 0.74
0.36
1.09
Price-to-Free-Cash-Flow 13.25
WBA's Price-to-Free-Cash-Flow is ranked higher than
64% of the 143 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.04 vs. WBA: 13.25 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
WBA' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.87  Med: 17.35 Max: 103.55
Current: 13.25
9.87
103.55
Price-to-Operating-Cash-Flow 11.01
WBA's Price-to-Operating-Cash-Flow is ranked higher than
50% of the 187 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.78 vs. WBA: 11.01 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
WBA' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.43  Med: 11.47 Max: 21.27
Current: 11.01
6.43
21.27
EV-to-EBIT 16.74
WBA's EV-to-EBIT is ranked lower than
53% of the 316 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 16.11 vs. WBA: 16.74 )
Ranked among companies with meaningful EV-to-EBIT only.
WBA' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.3  Med: 12.85 Max: 25.1
Current: 16.74
6.3
25.1
EV-to-EBITDA 12.85
WBA's EV-to-EBITDA is ranked lower than
53% of the 324 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 11.79 vs. WBA: 12.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
WBA' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.9  Med: 10.1 Max: 18.8
Current: 12.85
4.9
18.8
PEG Ratio 5.05
WBA's PEG Ratio is ranked lower than
73% of the 179 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.12 vs. WBA: 5.05 )
Ranked among companies with meaningful PEG Ratio only.
WBA' s PEG Ratio Range Over the Past 10 Years
Min: 0.5  Med: 1.64 Max: 8.78
Current: 5.05
0.5
8.78
Shiller PE Ratio 27.19
WBA's Shiller PE Ratio is ranked lower than
64% of the 86 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 22.04 vs. WBA: 27.19 )
Ranked among companies with meaningful Shiller PE Ratio only.
WBA' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.95  Med: 24.83 Max: 45.86
Current: 27.19
13.95
45.86
Current Ratio 1.30
WBA's Current Ratio is ranked higher than
56% of the 360 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.22 vs. WBA: 1.30 )
Ranked among companies with meaningful Current Ratio only.
WBA' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 1.66 Max: 2.36
Current: 1.3
1.19
2.36
Quick Ratio 0.90
WBA's Quick Ratio is ranked higher than
61% of the 360 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.76 vs. WBA: 0.90 )
Ranked among companies with meaningful Quick Ratio only.
WBA' s Quick Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.51 Max: 1.7
Current: 0.9
0.27
1.7
Days Inventory 38.05
WBA's Days Inventory is ranked higher than
52% of the 355 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.51 vs. WBA: 38.05 )
Ranked among companies with meaningful Days Inventory only.
WBA' s Days Inventory Range Over the Past 10 Years
Min: 35.11  Med: 53.52 Max: 60.84
Current: 38.05
35.11
60.84
Days Sales Outstanding 19.83
WBA's Days Sales Outstanding is ranked lower than
59% of the 274 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.78 vs. WBA: 19.83 )
Ranked among companies with meaningful Days Sales Outstanding only.
WBA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.04  Med: 14.78 Max: 24.17
Current: 19.83
11.04
24.17
Days Payable 47.84
WBA's Days Payable is ranked higher than
55% of the 269 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 43.02 vs. WBA: 47.84 )
Ranked among companies with meaningful Days Payable only.
WBA' s Days Payable Range Over the Past 10 Years
Min: 28.73  Med: 34.47 Max: 48.01
Current: 47.84
28.73
48.01

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.91
WBA's Dividend Yield % is ranked higher than
54% of the 477 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.95 vs. WBA: 1.91 )
Ranked among companies with meaningful Dividend Yield % only.
WBA' s Dividend Yield % Range Over the Past 10 Years
Min: 0.54  Med: 1.73 Max: 3.11
Current: 1.91
0.54
3.11
Dividend Payout Ratio 0.38
WBA's Dividend Payout Ratio is ranked higher than
60% of the 289 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.33 vs. WBA: 0.38 )
Ranked among companies with meaningful Dividend Payout Ratio only.
WBA' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.16  Med: 0.31 Max: 0.64
Current: 0.38
0.16
0.64
3-Year Dividend Growth Rate 8.50
WBA's 3-Year Dividend Growth Rate is ranked higher than
53% of the 184 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.40 vs. WBA: 8.50 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
WBA' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 3.8  Med: 13.7 Max: 26
Current: 8.5
3.8
26
Forward Dividend Yield % 2.00
WBA's Forward Dividend Yield % is ranked lower than
56% of the 464 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.20 vs. WBA: 2.00 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.63
WBA's 5-Year Yield-on-Cost % is ranked higher than
65% of the 526 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.96 vs. WBA: 3.63 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
WBA' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.03  Med: 3.3 Max: 5.94
Current: 3.63
1.03
5.94
3-Year Average Share Buyback Ratio -4.60
WBA's 3-Year Average Share Buyback Ratio is ranked lower than
73% of the 207 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: -0.70 vs. WBA: -4.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
WBA' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.9  Med: 0 Max: 3.5
Current: -4.6
-4.9
3.5

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 17.56
WBA's Price-to-Tangible-Book is ranked lower than
96% of the 314 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.07 vs. WBA: 17.56 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
WBA' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.94  Med: 3.98 Max: 58.76
Current: 17.56
1.94
58.76
Price-to-Intrinsic-Value-Projected-FCF 1.24
WBA's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
58% of the 228 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.47 vs. WBA: 1.24 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
WBA' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.73  Med: 2.58 Max: 18.64
Current: 1.24
0.73
18.64
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.69
WBA's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
63% of the 54 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.36 vs. WBA: 1.69 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.15
WBA's Price-to-Median-PS-Value is ranked lower than
51% of the 334 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.10 vs. WBA: 1.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
WBA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.56  Med: 1.11 Max: 3.19
Current: 1.15
0.56
3.19
Price-to-Peter-Lynch-Fair-Value 3.21
WBA's Price-to-Peter-Lynch-Fair-Value is ranked lower than
78% of the 102 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.71 vs. WBA: 3.21 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
WBA' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.94 Max: 6.3
Current: 3.21
0.57
6.3
Price-to-Graham-Number 3.97
WBA's Price-to-Graham-Number is ranked lower than
89% of the 265 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.48 vs. WBA: 3.97 )
Ranked among companies with meaningful Price-to-Graham-Number only.
WBA' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.99  Med: 2.02 Max: 8.07
Current: 3.97
0.99
8.07
Earnings Yield (Greenblatt) % 5.97
WBA's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 368 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.52 vs. WBA: 5.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
WBA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4  Med: 7.75 Max: 15.9
Current: 5.97
4
15.9
Forward Rate of Return (Yacktman) % 11.59
WBA's Forward Rate of Return (Yacktman) % is ranked higher than
66% of the 244 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.90 vs. WBA: 11.59 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
WBA' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 7  Med: 14.4 Max: 23.7
Current: 11.59
7
23.7

More Statistics

Revenue (TTM) (Mil) $116,701.00
EPS (TTM) $ 3.96
Beta0.81
Short Percentage of Float1.36%
52-Week Range $75.18 - 88.00
Shares Outstanding (Mil)1,070.10

Analyst Estimate

Aug17 Aug18 Aug19
Revenue (Mil $) 118,225 124,711 138,032
EPS ($) 4.94 5.25 6.11
EPS without NRI ($) 4.94 5.25 6.11
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.83%
Dividends per Share ($) 1.49 1.56 1.73
» More Articles for WBA

Headlines

Articles On GuruFocus.com
John Buckingham Picks Up 4 Retailers in 2nd Quarter Aug 18 2017 
Flashing Sell Sign? Aug 11 2017 
What Doesn’t Kill You Makes You Stronger Jul 11 2017 
Rite Aid: A David Einhorn Bargain Stock Jul 11 2017 
Introducing the Feature That Tells You Which Companies Recently Released Earnings Jul 05 2017 
Dividend Aristocrats in Focus: Walgreens Boots Alliance Jun 30 2017 
Options Trades: covered-call reports for Cisco Systems, Facebook, Procter & Gamble, Walgreens Boots Jun 19 2017 
InvestorsObserver releases covered-call reports for ACADIA Pharmaceuticals, Aerie Pharmaceuticals, B May 26 2017 
Walgreens Boots Alliance, Inc. (Nasdaq: WBA) and Comic Relief to Ring The Nasdaq Stock Market Closin May 23 2017 
General Mills, Hi-Crush Partners LP, JP Morgan Chase, PayPal Holdings Inc., and Walgreens Boots Alli May 02 2017 

More From Other Websites
Will the FTC Let Walgreens Go on a $5.2 Billion Rite Aid Shopping Spree? Aug 18 2017
Say ‘yes’ to every opportunity if you want to advance your career, says former Walgreens CEO Aug 18 2017
Will Walgreens Ever Get to Spend $5.2 Billion on 2,186 Rite Aid Stores? Aug 18 2017
Could the “New” Rite Aid Corporation (RAD) Go Broke? Aug 18 2017
Walgreens Boots to Gain From Altered Rite Aid Deal, Alliance Aug 18 2017
See what the IHS Markit Score report has to say about Walgreens Boots Alliance Inc. Aug 18 2017
Cisco Disappoints as Tech Lags; Walgreens-Rite Aid Test FTC Again -- ICYMI Aug 18 2017
Walgreens Tries to Avoid Another FTC Ordeal Aug 17 2017
Walgreens' (WBA) Research Website to Add Value in Healthcare Aug 17 2017
Has Rite Aid Stock Finally Bottomed Out? Aug 17 2017
Why You Shouldn’t Count Rite Aid Corporation (RAD) Stock Out Yet Aug 17 2017
Is There Anything Left on Rite Aid Corporation (RAD) Stock’s Carcass? Aug 16 2017
What You Should Know About Fred's Apart From Dismal Comps Aug 15 2017
Walgreens Launches Center for Health & Wellbeing Research Aug 15 2017
3 Dividend Stocks Ideal for Retirees Aug 14 2017
Edited Transcript of WBA earnings conference call or presentation 29-Jun-17 12:30pm GMT Aug 13 2017
New York City Bans Tobacco Sales In Pharmacies; Will Walgreens Follow CVS's Lead And Exit This... Aug 12 2017
Don’t Give Up on Rite Aid Corporation (RAD) Stock Now Aug 11 2017
Flashing For Sale Sign? Aug 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}